Keizo Fukushima1, Akira Okada1, Hiroyuki Oe1, Mika Hirasaki1, Mami Hamori2, Asako Nishimura2, Nobuhito Shibata2, Nobuyuki Sugioka3. 1. Department of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, 1-1-3 Minatojima, Chuo-ku, Kobe, 650-8586, Japan. 2. Department of Biopharmaceutics, Faculty of Pharmaceutical Science, Doshisha Women's College of Liberal Arts, Kyotanabe, Kyoto, 610-0395, Japan. 3. Department of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, 1-1-3 Minatojima, Chuo-ku, Kobe, 650-8586, Japan. nsugioka@pharm.kobegakuin.ac.jp.
Abstract
BACKGROUND AND OBJECTIVES: Forced diuresis, high-volume hydration with diuresis, is widely used as a prophylactic treatment against cisplatin nephrotoxicity. However, the details of the underlying mechanisms and the optimal protocol of forced diuresis remain unclear. The present study investigated the alterations in pharmacokinetics and pharmacodynamics (nephrotoxicity) of cisplatin with forced diuresis treatment. METHODS: Cisplatin (5 mg/kg) was intravenously injected to rats (5 rats/group, except for control group in pharmacodynamic study, n = 13) treated with or without forced diuresis 2-h pre- and post-hydration with 10% mannitol at different infusion rates (0.3, 1.0, and 3.0 mL/h). The unbound cisplatin concentrations in plasma and urine, and the platinum amount in the kidney were monitored in the pharmacokinetic studies. The plasma creatinine concentration was evaluated as an index of nephrotoxicity in the pharmacodynamic studies. RESULTS: Forced diuresis treatment did not significantly alter the plasma cisplatin pharmacokinetics but dramatically decreased the urine concentration of unbound cisplatin and its accumulation into the kidneys in a dose-dependent manner, and correspondingly, nephrotoxicity was dose-dependently attenuated by forced diuresis. The pharmacokinetic-pharmacodynamic analysis suggested that the urine cisplatin concentration has a comparable impact on the cisplatin-induced nephrotoxicity to that in plasma, probably owing to the reabsorption of cisplatin from urine, which can be attenuated by forced diuresis. CONCLUSIONS: These results indicated that the nephroprotective effect of forced diuresis is a pharmacokinetic-based drug-drug interaction possibly due to the inhibition of cisplatin reabsorption from urine. Monitoring of urine cisplatin concentration may lead to the optimization of a forced diuresis protocol with mannitol.
BACKGROUND AND OBJECTIVES: Forced diuresis, high-volume hydration with diuresis, is widely used as a prophylactic treatment against cisplatinnephrotoxicity. However, the details of the underlying mechanisms and the optimal protocol of forced diuresis remain unclear. The present study investigated the alterations in pharmacokinetics and pharmacodynamics (nephrotoxicity) of cisplatin with forced diuresis treatment. METHODS:Cisplatin (5 mg/kg) was intravenously injected to rats (5 rats/group, except for control group in pharmacodynamic study, n = 13) treated with or without forced diuresis 2-h pre- and post-hydration with 10% mannitol at different infusion rates (0.3, 1.0, and 3.0 mL/h). The unbound cisplatin concentrations in plasma and urine, and the platinum amount in the kidney were monitored in the pharmacokinetic studies. The plasma creatinine concentration was evaluated as an index of nephrotoxicity in the pharmacodynamic studies. RESULTS: Forced diuresis treatment did not significantly alter the plasma cisplatin pharmacokinetics but dramatically decreased the urine concentration of unbound cisplatin and its accumulation into the kidneys in a dose-dependent manner, and correspondingly, nephrotoxicity was dose-dependently attenuated by forced diuresis. The pharmacokinetic-pharmacodynamic analysis suggested that the urine cisplatin concentration has a comparable impact on the cisplatin-induced nephrotoxicity to that in plasma, probably owing to the reabsorption of cisplatin from urine, which can be attenuated by forced diuresis. CONCLUSIONS: These results indicated that the nephroprotective effect of forced diuresis is a pharmacokinetic-based drug-drug interaction possibly due to the inhibition of cisplatin reabsorption from urine. Monitoring of urine cisplatin concentration may lead to the optimization of a forced diuresis protocol with mannitol.
Authors: C M Mach; C Kha; D Nguyen; J Shumway; K M Meaders; M Ludwig; M Y Williams-Brown; M L Anderson Journal: J Clin Pharm Ther Date: 2017-03-09 Impact factor: 2.512
Authors: Mette Sprauten; Thomas H Darrah; Derick R Peterson; M Ellen Campbell; Robyn E Hannigan; Milada Cvancarova; Clair Beard; Hege S Haugnes; Sophie D Fosså; Jan Oldenburg; Lois B Travis Journal: J Clin Oncol Date: 2011-12-19 Impact factor: 44.544
Authors: Sheron Latcha; Edgar A Jaimes; Sujata Patil; Ilya G Glezerman; Swati Mehta; Carlos D Flombaum Journal: Clin J Am Soc Nephrol Date: 2016-04-12 Impact factor: 8.237
Authors: S Schweyer; A Soruri; O Meschter; A Heintze; F Zschunke; N Miosge; P Thelen; T Schlott; H J Radzun; A Fayyazi Journal: Br J Cancer Date: 2004-08-02 Impact factor: 7.640
Authors: Florent Puisset; Laurence Bigay-Game; Marie Noëlle Paludetto; Audrey Martel; Sophie Perriat; Audrey Rabeau; Jean Marie Canonge; Julien Mazieres Journal: Support Care Cancer Date: 2018-08-17 Impact factor: 3.603